This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CryoLife Management Presents At Lazard Capital Markets 8th Annual Healthcare Conference - Conference Call Transcript

CryoLife, Inc. (CRY)

Lazard Capital Markets 8th Annual Healthcare Conference

November 15, 2011, 15:00 p.m. ET


Steven Anderson - Chairman, President and CEO

Ashley Lee - EVP, COO and CFO


Patrick Donnelly - Lazard Capital Markets


Patrick Donnelly - Lazard Capital Markets

Let’s get started here. And thanks for coming. I’m Patrick Donnelly, I work on a Med Tech team here at Lazard. I’m happy to have Steven Anderson and Ashley Lee with us from CryoLife, will present for about 15 minutes and have some time for Q&A as well. So, pass it over to you.

Steven Anderson

Thank you, Patrick. I’m Steve Anderson, and I’m the Founder and CEO of CryoLife. And with me today is Ashley Lee, the company’s Executive VP and CFO.

Our first line today outlines our forward-looking statements and is available in the copy of the presentation that’s posted on our Investor Relations website and I encourage you to review the forward-looking statements and other risk factors as detailed in our Form 10-K, which was filed on December 31, 2010.

CryoLife is a medical technology company, focused on products that address complex cardiac and vascular reconstruction. We have a diversified business composed of mature cash generating products and tissue preservation services and surgical sealants which are complimented by a number of earlier staged products that provide us with significant and high growth market opportunities. We have a strong sales organization with well established relationships with cardiac and vascular surgeons throughout the world.

The company’s physician relationships are further strengthened by our physician and surgical training programs. We are leveraging this unique position to expand utilization of our emerging products. And finally we believe we have a tremendous opportunity to further leverage our existing core business, our sales force and infrastructure to drive growth of additional new products in the cardiac and vascular surgery space. We are using our strong balance sheet to actively search for potential acquisitions and invest in research and development to advance our internal pipeline of products and accelerate our growth.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs